A novel risk analysis of clinical reference dosimetry based on failure modes and effects analysis.


Journal

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
ISSN: 1724-191X
Titre abrégé: Phys Med
Pays: Italy
ID NLM: 9302888

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 02 10 2018
revised: 29 12 2018
accepted: 22 01 2019
entrez: 3 3 2019
pubmed: 3 3 2019
medline: 26 3 2019
Statut: ppublish

Résumé

The output of a linear accelerator (linac) is one of the most important quality assurance (QA) factors in radiotherapy. However, there is no quantitative rationale for frequency and tolerance. The purpose of this study is to develop a novel risk analysis of clinical reference dosimetry based on failure modes and effects analysis (FMEA). Clinical reference dosimetry data and the daily output data of two linacs (Clinac iX and Clinac 6EX) at Hiroshima University Hospital were analyzed. The analysis involved the number of patients per year for five types of fractionations. Risk priority number (RPN) is defined as the product of occurrence (O), severity (S), and detectability (D) in standard FMEA. In addition, we introduced "severity due to output drifting" (mean output change per day) (S') and the number of patients per year for five types of fractionations (W). We calculated the RPN = O × S × D × S' × W and quantitatively evaluated the risk for clinical reference dosimetry. Fewer fractions and less output calibration frequency resulted in higher RPN. Since clinical reference dosimetry data has a drift effect, which is missing in human processes, it was essential to use S' in addition to standard FMEA. Moreover, the parameter W was important in evaluating interinstitutional QA for clinical reference dosimetry. The relative risk of Clinac 6EX to Clinac iX was different approximately by twofold. We developed a novel index that can quantitatively evaluate risk for clinical reference dosimetry of each facility and machines in common on the basis of FMEA.

Identifiants

pubmed: 30824151
pii: S1120-1797(19)30014-6
doi: 10.1016/j.ejmp.2019.01.014
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-65

Informations de copyright

Copyright © 2019 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Auteurs

Yusuke Ochi (Y)

Radiation Therapy Section, Department of Clinical Support, Hiroshima University Hospital, Hiroshima 734-8551, Japan; Department of Radiation Oncology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.

Akito Saito (A)

Department of Radiation Oncology, Hiroshima University Hospital, Hiroshima 734-8551, Japan. Electronic address: akito@hiroshima-u.ac.jp.

Daisuke Kawahara (D)

Radiation Therapy Section, Department of Clinical Support, Hiroshima University Hospital, Hiroshima 734-8551, Japan; Department of Radiation Oncology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.

Tatsuhiko Suzuki (T)

Department of Radiation Oncology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.

Masato Tsuneda (M)

Department of Radiation Oncology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan; Department of Radiation Oncology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.

Sodai Tanaka (S)

Department of Nuclear Engineering and Management, School of Engineering, University of Tokyo, Tokyo 113-8656, Japan.

Teiji Nishio (T)

Department of Medical Physics, Graduate School of Medical Science, Tokyo Women's Medical University, Tokyo 162-8666, Japan.

Shuichi Ozawa (S)

Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima 732-0057, Japan; Department of Radiation Oncology, Institute of Biomedical and Health Sciences, Hiroshima University, Japan.

Yuji Murakami (Y)

Department of Radiation Oncology, Institute of Biomedical and Health Sciences, Hiroshima University, Japan.

Yasushi Nagata (Y)

Department of Radiation Oncology, Institute of Biomedical and Health Sciences, Hiroshima University, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH